BMI-2004 (A Recombinant Hyaluronidase): Advancing Subcutaneous Drug Delivery - Phase 1 Clinical Trial Results to Be Presented at the 15th Annual Bioprocessing Summit in Boston ...Middle East

BOSTON, Aug. 10, 2023 /PRNewswire/ -- BMI Korea Co., LTD. ("BMI Korea"), a leading Korean biotech company specializing in biologics development, introduces its novel recombinant hyaluronidase, BMI-2004, and shares Phase 1 clinical trial results at the 15th Annual Bioprocessing Summit...

Hence then, the article about bmi 2004 a recombinant hyaluronidase advancing subcutaneous drug delivery phase 1 clinical trial results to be presented at the 15th annual bioprocessing summit in boston was published today ( Thursday 10/08/2023 - 08:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BMI-2004 (A Recombinant Hyaluronidase): Advancing Subcutaneous Drug Delivery - Phase 1 Clinical Trial Results to Be Presented at the 15th Annual Bioprocessing Summit in Boston )

Also on site :

• Heavy police presence in NW suburb with roads blocked due to ‘isolated incident'
• The top pandemic threats as WHO declares Ebola emergency
• Starbucks Expands Its Summer Menu With 2 Vibrant New Drinks